10-Q: VitaNova Reports Q3 Loss Amid Soaring G&A, Strong Revenue Growth

VitaNova Life Sciences Corp. reported a net loss for Q3 and the nine months ended January 31, 2026, despite significant revenue growth driven by its dietary supplement segment, primarily due to increased general and administrative expenses and cost of revenue.

Summary

• Net loss of $44,362 for the three months ended January 31, 2026, compared to net income of $72,978 in the prior year period.
• Net loss of $54,853 for the nine months ended January 31, 2026, a significant decline from net income of $50,414 in the prior year period.
• Total revenue increased by 130% to $709,625 for the three months and by 75% to $1,240,639 for the nine months ended January 31, 2026, primarily driven by the dietary supplement products segment.
• Gross profit margin decreased to 45% for the three months and 52% for the nine months ended January 31, 2026, from 61% and 59% respectively in the prior year periods.
• General and administrative expenses surged by 616% to $219,601 for the three months and by 216% to $405,338 for the nine months, mainly due to increased legal and professional fees.
• Cash provided by operating activities significantly improved to $386,094 for the nine months ended January 31, 2026, compared to cash used of $286,363 in the prior year.
• The company completed a 1-for-3 reverse stock split effective January 27, 2026, and changed its name to VitaNova Life Sciences Corporation with ticker VNOV on January 9, 2026.
• Material weaknesses in internal controls over financial reporting were identified, including a lack of a functioning audit committee and ineffective controls over period-end financial disclosure.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a concerning report. While revenue growth is impressive, the significant decline in profitability, coupled with soaring G&A expenses and identified internal control weaknesses, overshadows the top-line performance and raises serious questions about operational efficiency and governance.

Positives

• Strong revenue growth of 130% for the three months and 75% for the nine months ended January 31, 2026, primarily from the dietary supplement segment.
• Significant improvement in cash flow from operating activities, moving from a net cash outflow of $286,363 to a net cash inflow of $386,094 for the nine months ended January 31, 2026.
• Cash balance increased to $1,168,904 as of January 31, 2026, from $782,810 as of April 30, 2025.
• Establishment of VitaNova Global Foods Corporation in March 2026 indicates potential expansion into new food-related ventures.

Negatives

• Shift from net income to a net loss of $44,362 for the three months and $54,853 for the nine months ended January 31, 2026.
• Significant increase in general and administrative expenses by 616% for the three months and 216% for the nine months, largely due to legal and professional fees.
• Gross profit margin declined from 61% to 45% for the three months and from 59% to 52% for the nine months ended January 31, 2026.
• The Consulting Service Segment consistently reported significant segment losses, totaling $(251,634) for the three months and $(467,435) for the nine months ended January 31, 2026.
• Income from operations decreased by 57% for the three months and 10% for the nine months ended January 31, 2026.

Risks

• Concentration of Cash: $493,283 of cash held by financial institutions as of January 31, 2026, was uninsured by FDIC, exposing the company to potential loss if a bank becomes insolvent.
• Major Customer Concentration: For the three months ended January 31, 2026, three customers accounted for 74.05% of total revenue and $843,130 in accounts receivable. For the nine months, three customers accounted for 55.92% of total revenue and $564,380 in accounts receivable. Loss of any of these major customers could significantly impact revenue and financial stability.
• Major Vendor Concentration: One vendor accounted for 100% of the company's purchase cost for both the three and nine months ended January 31, 2026, creating a single point of failure in the supply chain.
• Internal Control Weaknesses: Identified material weaknesses include a lack of a functioning audit committee (due to insufficient independent members and outside directors) and ineffective controls over period-end financial disclosure and reporting processes, which could lead to material misstatements in future financial statements.
• Reliance on Estimates: Financial statements rely on management estimates and assumptions, such as sales returns, inventory, and income tax valuation allowances, which could differ from actual results.

Future Outlook

The company continues to seek additional opportunities to potentially increase its profits in 2026. Management has initiated steps to strengthen oversight and financial reporting processes to remediate identified material weaknesses in internal controls, expecting full implementation and operation to resolve these issues.

Management Comments

• "In the opinion of management, the consolidated financial statements contain all material adjustments, consisting only of normal adjustments considered necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented."
• "Management believes that the material weaknesses set forth above did not have an effect on our financial results. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our Board of Directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods."
• "To address these material weaknesses, management has initiated steps to strengthen oversight and financial reporting processes, including implementing more formal procedures for preparing and reviewing period-end financial statements and disclosures."
• "We expect that once these measures are fully implemented and operating for a sufficient period, we will remediate the identified weaknesses."

Industry Context

StockSavvy.ai notes that VitaNova's strong revenue growth in dietary supplements aligns with broader trends in the health and wellness industry, which continues to see robust consumer demand. However, the significant increase in general and administrative expenses, particularly legal and professional fees, and the resulting net loss, suggest challenges in scaling operations profitably or managing overhead effectively, which could be a red flag in a competitive market where cost efficiency is paramount. The identified internal control weaknesses are also a concern, potentially hindering investor confidence compared to more mature, well-governed industry peers.

Comparison to Industry Standards

• VitaNova's 130% revenue growth in the dietary supplement segment for the three months ended January 31, 2026, significantly outpaces the average growth rates of many established dietary supplement companies, which typically range from 5-15% annually. For example, industry leaders like Herbalife Nutrition or GNC Holdings, while larger, often report single-digit to low double-digit growth.
• The decline in gross profit margin from 61% to 45% (three months) and 59% to 52% (nine months) suggests potential pricing pressures, increased cost of goods, or a shift in product mix towards lower-margin items. This contrasts with some industry benchmarks where stable or improving gross margins are often seen as indicators of strong brand power and efficient supply chains.
• The substantial increase in general and administrative expenses (616% for three months, 216% for nine months) is significantly higher than typical industry expense growth, even for rapidly expanding companies. This level of increase, attributed to legal and professional fees, could indicate underlying operational or compliance issues that are not common among well-managed peers.
• The identified material weaknesses in internal controls, particularly the lack of a functioning audit committee, fall below standard corporate governance practices expected of publicly traded companies, regardless of size. Larger, more established companies like Amway or Nature's Bounty (now part of Kenvue) maintain robust internal control frameworks and independent audit committees to ensure financial integrity and investor trust.

Corporate Governance

Related Party Transactions

• Steve Niu (CFO) was granted 20,000 common stocks at $0.05 per share, subject to one year of service vesting, with $0 share-based compensation recognized for the nine months ended January 31, 2026, and $1,750 for the prior year period.
• Steve Niu received compensation of $6,000 for the three months and $18,000 for the nine months ended January 31, 2026.
• Rose Kelly (CEO and Director) received compensation of $15,521 for the three months and $46,565 for the nine months ended January 31, 2026.
• Robert M. Kelly (family member of Ms. Kelly) received compensation of $6,000 for the three months and $6,000 for the nine months ended January 31, 2026.
• The company received proceeds of $99,000 from a related party for the nine months ended January 31, 2025.

Stakeholder Impact

• Shareholders: The net loss and declining profitability, coupled with identified internal control weaknesses, could negatively impact shareholder value and confidence. The 1-for-3 reverse stock split may also be viewed with caution.
• Management/Employees: Compensation for key management personnel is disclosed, and personnel costs decreased overall for the nine-month period, potentially impacting employee morale or retention.
• Customers: High customer concentration means the loss of a few major customers could severely impact revenue, potentially affecting product availability or service quality for remaining customers.
• Suppliers/Vendors: 100% reliance on a single vendor for purchase costs creates significant supply chain risk, which could affect product availability and pricing.
• Regulatory Authorities: The identified material weaknesses in internal controls will likely draw scrutiny from regulatory bodies like the SEC, requiring diligent remediation efforts.

Next Steps

• Management plans to strengthen oversight and financial reporting processes to remediate identified material weaknesses in internal controls.
• The company continues to look for other opportunities to potentially increase profits in 2026.
• The newly established VitaNova Global Foods Corporation in March 2026 suggests future expansion into food-related ventures.

Key Dates

Recommendation

Despite strong top-line revenue growth, the company's significant shift to a net loss, coupled with a sharp increase in general and administrative expenses and a decline in gross profit margins, indicates severe profitability challenges. The identified material weaknesses in internal controls and high customer/vendor concentration introduce substantial operational and governance risks. These factors collectively suggest a deteriorating financial position and increased risk profile, warranting a 'sell' recommendation for seasoned investors.

Keywords

VitaNova Life Sciences, VNOV, 10-Q, Quarterly Report, Dietary Supplements, Consulting Services, Financial Results, Net Loss, Revenue Growth, Internal Controls, Reverse Stock Split, SEC Filing, Healthcare Products, Corporate Governance